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Background
The cardiac hormone atrial natriuretic peptide (ANP)
induces natriuresis, vasodilation and inhibits aldosterone
through the activation of the guanylyl cyclase A receptor
(GC-A) and the second messenger cGMP. ANP pos-
sesses also metabolic properties enhancing lipolysis and
release of the adipokine adiponectin. Previous studies in
general populations reported that the minor G allele of
the ANP genetic variant rs5068 is associated with
increased circulating levels of ANP and B-type natriure-
tic peptide, lower blood pressure (BP), and reduced risk
of hypertension. We recently reported that in the gen-
eral population from Olmsted County, MN, USA the G
allele of rs5068 is associated not only with increased
levels of ANP and lower BP but also with lower BMI,
prevalence of obesity and metabolic syndrome.
To advance our understanding of the phenotype asso-
ciated with rs5068 we analyzed a community-based cohort
from Sicily, Italy. Our second aim was to advance a poten-
tial therapeutics for cardiometabolic disease employing a
novel long-acting ANP, MANP whose biological actions
were defined in canines and in a rat model of metabolic
syndrome.
Results
In a Sicilian cohort (n=812) genotype frequencies of
rs5068 are AA: 93.5%, AG: 6.4%, and GG: 0.1%. After
adjusting for age and gender, the minor G allele is asso-
ciated with lower BMI (estimate (SE): -1.7 (0.8) kg/m2,
p=0.04) and prevalence of metabolic syndrome (p=0.02),
obesity tends to be less prevalent (p=0.07). Independently
of age, gender and BMI, the minor=allele is associated
with lower systolic blood pressure (estimate (SE): -6.0 (2.5)
mmHg, p=0.02) and prevalence of hypertension (odds
ratio: 0.41; 95% CI 0.20 to 0.83; p=0.01). In canines, subcu-
taneous administration of MANP (10 ug/kg) resulted in a
ten-fold greater activation of plasma cGMP (AUC: 5095
+-1365 vs 676+-211 pmol/ml/min, p<0.05) and a sustained
reduction in BP (p<0.05) when compared to ANP. In a rat
model of metabolic syndrome, intravenous administration
of MANP (0.13ug/kg/min) significantly decreased BP
when compared to baseline (171 vs 186 mmHg, p=0.0024)
and increased plasma levels of adiponectin (37 vs 27 ng/
ml, p=0.03).
Conclusion
The association between the minor allele of rs5068 and a
“favorable” cardiometabolic phenotype is now replicated
in a Mediterranean population. In canines, the novel
natriuretic peptide MANP has a sustained cGMP-
mediated blood pressure lowering action. In a rodent
model of metabolic syndrome, MANP decreases blood
pressure and mediates increase of circulating adiponectin.
Our findings support further studies to evaluate MANP as
a possible therapeutic for cardiometabolic disease.
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